G6PD and malaria: More recently, the third generation of the CareStart G6PD RDT (www.accessbio.net) was found to be more capable and reliably detected moderate and severe G6PD-deficient individuals (enzyme activity < 30%), suggesting that this novel point-of-care is a promising tool for tailoring appropriate primaquine treatment of malaria elimination by excluding individuals with severe G6PDd for primaquine treatment.34